V8 Peptides — Engineered Performance
Research Library
Tirzepatide: FDA, HHS and WADA Documents Read
TirzepatideRegulatory

Tirzepatide: FDA, HHS and WADA Documents Read

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

As read on 17 November 2026: FDA records Zepbound (tirzepatide) as approved on 8 November 2023 and determined on 19 December 2024 that the tirzepatide product shortage was resolved; tirzepatide is not named in 21 CFR 216.23(a), in Appendix A of the HHS policy notice of 30 October 2026, or in the WADA 2026 List. This summarizes documents only and gives no legal conclusion or advice.

Tirzepatide is the active ingredient of drugs approved by FDA, and it is also discussed in searches about compounding and research materials. This article reads the primary documents that bear on those topics and states what each says, with the date it was read (17 November 2026). The documents are FDA's approval package and news release for Zepbound, FDA's December 2024 drug shortage determination memorandum, FDA's section 503A pages, 21 CFR 201.128, a Federal Register notice and policy document from the Department of Health and Human Services (HHS) dated 30 October 2026, and the World Anti-Doping Agency (WADA) 2026 Prohibited List. Law-firm and news summaries were not used. The article draws no legal conclusion, gives no advice and does not say whether any activity involving tirzepatide is lawful. The wider library discussion is in research peptide legal status in the US and the tirzepatide research overview.

V8 products are labeled for laboratory research use only. This article describes documents and states no legal conclusion.

The molecule, as the literature describes it

Tirzepatide was reported under the code LY3298176 (Coskun et al., 2018) as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, and a 2020 paper (Willard et al.) characterizes it as an imbalanced and biased dual GIP and GLP-1 receptor agonist. Receptor pharmacology is covered in the research overview and brand-name chemistry in tirzepatide, Mounjaro and Zepbound. Everything below concerns regulatory documents, not pharmacology.

Document 1: FDA approval record for Zepbound

FDA's approval package for NDA 217806 identifies the product as Zepbound (tirzepatide), sponsor Eli Lilly and Company, with an approval date of 8 November 2023. FDA's news release of the same date, "FDA Approves New Medication for Chronic Weight Management," states that "tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro." The approval documents describe an approved drug product and its labeling. They do not address research-use-only materials, and this article does not read them as doing so.

Document 2: FDA's drug shortage determination of December 2024

FDA's memorandum on the resolution of the tirzepatide product shortage and supply status (title in the references), dated 19 December 2024 and addressed to the CDER Drug Shortage File, states that tirzepatide products were first added to FDA's drug shortage list on 15 December 2022, that FDA determined the shortage resolved and removed them from the list on 2 October 2024, and that FDA reevaluated that decision and determined upon reevaluation that the shortage is resolved. The memorandum bases that conclusion on information from Eli Lilly and Company about production, inventory and projected supply. It refers to FDA's policies for compounders under sections 503A and 503B of the FD&C Act that depend on shortage-list status, and states time periods after the memorandum date: for outsourcing facilities under section 503B, 90 calendar days, until 19 March 2025. The memorandum concerns finished approved drug products. It does not mention research materials.

Document 3: FDA's section 503A pages

FDA's page "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" (read 17 November 2026) states that state-licensed physicians and pharmacists that compound under section 503A "may only compound drug products using bulk drug substances" that comply with an applicable USP or NF monograph if one exists, are components of FDA-approved drug products if no monograph exists, or appear on FDA's 503A bulks list. Because tirzepatide is a component of FDA-approved drug products, the second route is the one the page's wording would connect to it; the page itself does not discuss tirzepatide. The regulation that holds the list, 21 CFR 216.23(a) (eCFR, read 17 November 2026), names six substances, and tirzepatide is not one of them. The page also states that bulk drug substances "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA."

Document 4: the HHS notice of 30 October 2026

The Federal Register notice (91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496) announces a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It states that the draft policy "does not establish any rights for any person and is not binding on HHS or the public." Appendix A of the linked policy document, read 17 November 2026, lists six substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Tirzepatide does not appear in the policy document text read. The policy document also states the Secretary's determination that the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). It is quoted as worded and is not interpreted here; the Federal Register notice itself does not mention research-use-only materials.

Document 5: FDA's regulation on intended use

21 CFR 201.128, "Meaning of 'intended uses'" (eCFR, read 17 November 2026), states that intended uses "refer to the objective intent of the persons legally responsible for the labeling of an article," that intent "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," and that it "may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives." FDA's warning letter MARCS-CMS 694608 of 10 December 2024 applies that reasoning to one recipient's website and products (retatrutide, cagrilintide, mazdutide, semaglutide, survodutide and sermorelin; tirzepatide is not among the products it names). It states that, despite "FOR RESEARCH USE ONLY" statements on labeling, evidence from the website established that the products were intended to be drugs for people. That is FDA's reasoning in one letter about specific products and statements, reported as published and not as a general rule.

Document 6: the WADA 2026 Prohibited List

The 2026 List states that it "shall come into effect on 1 January 2026." The English PDF on wada-ama.org was read on 17 November 2026, including its alphabetical index. The word tirzepatide does not appear in it, and neither does "GLP-1." "Not named" describes that text only and is not a statement about any other rule.

Where each document speaks

DocumentIssuer and dateWhat it states about tirzepatideWhat it does not state
Zepbound approval package, NDA 217806FDA; approval 8 November 2023Approved drug product; sponsor Eli Lilly and CompanyAnything about research materials
News releaseFDA; 8 November 2023Tirzepatide already approved as MounjaroAnything about other uses
Shortage memorandumFDA; 19 December 2024Shortage of tirzepatide products determined resolvedAnything about research materials
503A page and 21 CFR 216.23(a)FDA; read 17 November 2026Three routes for bulk substances; tirzepatide not on the list in the regulationTirzepatide individually
HHS notice and policy, Appendix AHHS; 30 October 2026Tirzepatide is not one of the six listed peptidesAnything about approved drugs
21 CFR 201.128FDA; eCFR read 17 November 2026Intended use judged from objective evidence including labeling claimsTirzepatide individually
2026 Prohibited ListWADA; in force 1 January 2026Tirzepatide is not namedAnything about unnamed compounds

Dates in this article

DateEventSource
15 December 2022Tirzepatide products first added to FDA's shortage listFDA memorandum
8 November 2023Zepbound approval date, NDA 217806FDA
2 October 2024Shortage determined resolved and products removed from the list (first determination)FDA memorandum
10 December 2024FDA warning letter MARCS-CMS 694608 issuedFDA
19 December 2024FDA reevaluation memorandum: shortage resolvedFDA memorandum
1 January 2026WADA 2026 Prohibited List takes effectWADA
30 October 2026HHS notice published, 91 FR 68526Federal Register
17 November 2026Date these documents were read—

Reading dates and drafts correctly

Three habits help with regulatory material. First, check the document type: a shortage memorandum, a draft policy notice and a regulation are different things, and the HHS notice says its draft policy is not binding. Second, record the access date, because lists and drafts change and this article reflects 17 November 2026 only. Third, note the issuer, because FDA, HHS and WADA are separate bodies and each speaks only for itself. For lot documentation, see how to read a COA and the COA page.

Limits of this article

This article does not cover state law, customs and import rules, foreign regulation, patents or institutional policy, and it does not assess whether any seller or activity complies with any law. Reading the FDA memorandum for this article covered its introduction and the passages quoted, not every page. Related reading: tirzepatide reconstitution and handling for bench arithmetic and the calculator. The tirzepatide product page and the shop list specifications for laboratory research use only.

Frequently asked questions

Is tirzepatide an FDA-approved drug ingredient?

FDA's approval package for NDA 217806 records Zepbound (tirzepatide), approved 8 November 2023, and FDA's news release says tirzepatide is already approved as Mounjaro.

What did FDA decide about the tirzepatide shortage?

In a memorandum dated 19 December 2024, FDA stated that on reevaluation it determined the tirzepatide product shortage is resolved. It had first removed the products from the shortage list on 2 October 2024.

Is tirzepatide named in the regulation listing 503A bulk substances?

No. 21 CFR 216.23(a), as read on 17 November 2026, names six other substances.

Is tirzepatide on the HHS policy's Appendix A?

No. As read on 17 November 2026, Appendix A lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

Is the HHS policy binding?

The notice states that the draft policy does not establish any rights for any person and is not binding on HHS or the public.

Does the WADA 2026 List name tirzepatide?

The English 2026 List text read on 17 November 2026 does not contain tirzepatide or the term GLP-1.

What does 21 CFR 201.128 say about intended use?

It states that intended use refers to the objective intent of the persons responsible for labeling, which may be shown by labeling claims, advertising, statements and the circumstances of distribution.

What did FDA say about research-use-only labels in the 2024 warning letter?

In that letter, to one recipient about specific products other than tirzepatide, FDA stated that website evidence established the products were intended to be drugs for people despite "FOR RESEARCH USE ONLY" labeling. It is that letter's reasoning only.

Do these documents say tirzepatide may be sold for any purpose?

No. They describe approvals, a shortage determination, compounding conditions and a regulation on intended use. This article draws no conclusion about any sale.

Does this article say whether anything is legal?

No. It reports what documents state, with dates, and draws no legal conclusion.

Related reading: Research Peptide Documents in 2026: HHS, FDA and WADA Read, BPC-157 Regulatory Documents in 2026: A Dated Reading, BPC-157 and TB-500: US Regulatory Documents in 2026, PT-141 US Regulatory Status: A Primary-Source Summary.

References

  1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  2. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
  3. U.S. Food and Drug Administration. Approval Package, NDA 217806, Zepbound (tirzepatide), approval date November 8, 2023, accessdata.fda.gov/drugsatfda_docs/nda/2024/217806Orig1s000Approv.pdf; and FDA news release "FDA Approves New Medication for Chronic Weight Management," 8 November 2023, fda.gov (both read 17 November 2026).
  4. U.S. Food and Drug Administration, CDER Drug Shortage Staff. Resolution of Tirzepatide Injection Product Shortage and Supply Status. Memorandum, 19 December 2024. fda.gov/media/185577/download (read 17 November 2026).
  5. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91:68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances (read 17 November 2026).
  6. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91:68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances (read 17 November 2026).
  7. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document, Appendix A). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (read 17 November 2026).
  8. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act; and Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov (both read 17 November 2026). 21 CFR 216.23, ecfr.gov (read 17 November 2026).

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.